PDL Settles Novartis IP Row With Lucentis Payments

Law360, New York (February 28, 2011, 5:05 PM EST) -- PDL BioPharma Inc. on Monday said it had resolved a wide-ranging patent battle with Novartis AG by agreeing to pay the Swiss drug giant an unspecified amount based on its sales of eye drug Lucentis.

The European Patent Office's Technical Board of Appeal on Monday also confirmed cancelling a hearing in which Novartis, UCB Pharma SA and BioTransplant Inc. planned to appeal a 2007 ruling upholding one of PDL's key European patents — a withdrawal directly related to PDL's settlement with Novartis.

The EPO's decision effectively...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.